CHISON MEDICAL(SH:688358) Sou Hu Cai Jing·2025-10-31 12:17Core Viewpoint - Xiangsheng Medical (688358) has shown a slight increase in stock price, with a closing price of 34.94 yuan on October 31, 2025, reflecting a 2.92% rise, amidst mixed capital flows from different investor types [1][2]. Financial Performance - For the first three quarters of 2025, Xiangsheng Medical reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27% [3]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year, while the net profit after deducting non-recurring items was 86.97 million yuan, a decrease of 2.69% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 107 million yuan, down 6.68% year-on-year, but the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [3]. Market Position and Ratios - Xiangsheng Medical's total market capitalization is 3.918 billion yuan, with a net asset value of 1.4 billion yuan [3]. - The company has a price-to-earnings (P/E) ratio of 31.28, which is significantly lower than the industry average of 62.61, indicating a potentially undervalued stock [3]. - The gross margin stands at 59.82%, higher than the industry average of 51.22%, while the net margin is 27.37%, compared to the industry average of 9.57% [3]. Capital Flow Analysis - On October 31, 2025, the net inflow of main funds was 5.57 million yuan, accounting for 7.14% of the total transaction volume, while retail investors experienced a net outflow of 1.33 million yuan [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with varying net inflows and outflows from main funds, retail investors, and speculative funds [2]. Institutional Ratings - In the last 90 days, four institutions have provided ratings for Xiangsheng Medical, all of which are buy ratings, indicating positive sentiment from analysts [4].